Solid Tumor

© GettyImages/Cecilie_Arcurs

Novartis inks contract manufacturing deal with Carisma

By Jane Byrne

Novartis continues down the third-party manufacturing route, as it secures an agreement with Carisma Therapeutics, a firm developing a cell therapy platform focused on engineered macrophage-based therapeutics.

(Image: Getty/wildpixel)

CAR-T for solid tumors drives industry to innovate

By Maggie Lynch

ICT is developing upon CAR-T cell technology to enable T-cells to persist against cancer’s attempt to program death into a patient’s defensive T-cells, which could potentially treat solid tumors.

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All suppliers